Research

Select Publications

Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer (2021)

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model (2020)

Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma (2019)

Ascorbic acid in cancer treatment: let the phoenix fly (2018)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis (2023)

Derivative survival analyses: Analysis methods to derive survival outcomes for the remainder patient cohort without individual patient data (2024)

Immune evasion in renal cell carcinoma: biology, clinical translation, future directions (2021)

HIF1α is not a target of 14q deletion in clear cell renal cancer (2020)

Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy (2020)

Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting? (2020)

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells (2017)

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective (2016)

Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist (2017)

Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells (2017)

Protocol Modification To Determine The Cytotoxic Potential Of Drugs Using Cell Viability Assays That Rely On The Reducing Property Of Viable Cells (2017)

Role of DNA methylation in renal cell carcinoma (2015)

Latest/ Preprint

Hypoxia inducible factors drive miRNA-mediated downregulation of L2HGDH and HIF1A in clear cell renal cancer independent of 14q deletion (2024)